Humana (NYSE:HUM) Price Target Raised to $529.00

Humana (NYSE:HUMGet Rating) had its target price raised by Mizuho from $500.00 to $529.00 in a research report released on Thursday morning, The Fly reports. They currently have a maintains rating on the insurance provider’s stock.

HUM has been the topic of a number of other reports. UBS Group raised shares of Humana from a neutral rating to a buy rating and boosted their price objective for the company from $486.00 to $520.00 in a report on Wednesday, April 13th. Wells Fargo & Company upped their price target on shares of Humana from $512.00 to $514.00 and gave the company an overweight rating in a report on Wednesday, May 25th. Sanford C. Bernstein initiated coverage on shares of Humana in a report on Thursday, May 26th. They issued a market perform rating and a $506.00 price target on the stock. StockNews.com raised shares of Humana from a buy rating to a strong-buy rating in a report on Wednesday, April 20th. Finally, Loop Capital initiated coverage on shares of Humana in a report on Thursday, June 16th. They issued a buy rating and a $510.00 price target on the stock. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $511.44.

Humana Price Performance

Shares of HUM opened at $482.00 on Thursday. The firm has a market capitalization of $60.97 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.42 and a beta of 0.80. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.53 and a quick ratio of 1.53. Humana has a 1-year low of $351.20 and a 1-year high of $497.47. The company’s fifty day moving average price is $462.13 and its 200-day moving average price is $440.76.

Humana (NYSE:HUMGet Rating) last announced its quarterly earnings data on Wednesday, July 27th. The insurance provider reported $8.67 earnings per share for the quarter, beating analysts’ consensus estimates of $7.67 by $1.00. The firm had revenue of $23.66 billion for the quarter, compared to analyst estimates of $23.44 billion. Humana had a net margin of 3.51% and a return on equity of 17.27%. The business’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same period in the previous year, the company earned $6.89 earnings per share. On average, equities research analysts predict that Humana will post 24.65 EPS for the current year.

Insider Buying and Selling

In related news, insider Samir Deshpande sold 3,957 shares of the company’s stock in a transaction dated Tuesday, May 3rd. The shares were sold at an average price of $434.19, for a total transaction of $1,718,089.83. Following the completion of the transaction, the insider now owns 5,529 shares in the company, valued at approximately $2,400,636.51. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of HUM. Tcwp LLC acquired a new position in shares of Humana during the 1st quarter worth about $25,000. WFA of San Diego LLC acquired a new stake in Humana in the 2nd quarter valued at about $30,000. BerganKDV Wealth Management LLC raised its holdings in Humana by 885.7% in the 4th quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 62 shares during the last quarter. Riverview Trust Co acquired a new stake in Humana in the 1st quarter valued at about $32,000. Finally, Newbridge Financial Services Group Inc. raised its holdings in Humana by 42.3% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 74 shares of the insurance provider’s stock valued at $35,000 after acquiring an additional 22 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Humana Company Profile

(Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Articles

The Fly logo

Analyst Recommendations for Humana (NYSE:HUM)

Want More Great Investing Ideas?

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.